Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Read more about Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.
Targeting therapy-persistent residual disease. Read more about Targeting therapy-persistent residual disease.
Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. Read more about Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Read more about PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.
KRAS degradation averts PDAC chemoresistance. Read more about KRAS degradation averts PDAC chemoresistance.
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Read more about Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
Understanding inequities in precision oncology diagnostics. Read more about Understanding inequities in precision oncology diagnostics.
A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression. Read more about A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression.
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. Read more about A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Read more about A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets.
